Literature DB >> 33443228

The long term effect of pulmonary tuberculosis on income and employment in a low income, urban setting.

Jamilah Meghji1,2, Stefanie Gregorius3,4, Jason Madan5, Fatima Chitimbe2, Rachael Thomson3, Jamie Rylance3,2, Ndaziona Pk Banda6, Stephen B Gordon3,2, Elizabeth L Corbett7, Kevin Mortimer3, Stephen Bertel Squire3.   

Abstract

BACKGROUND: Mitigating the socioeconomic impact of tuberculosis (TB) is key to the WHO End TB Strategy. However, little known about socioeconomic well-being beyond TB-treatment completion. In this mixed-methods study, we describe socioeconomic outcomes after TB-disease in urban Blantyre, Malawi, and explore pathways and barriers to financial recovery.
METHODS: Adults ≥15 years successfully completing treatment for a first episode of pulmonary TB under the National TB Control Programme were prospectively followed up for 12 months. Socioeconomic, income, occupation, health seeking and cost data were collected. Determinants and impacts of ongoing financial hardship were explored through illness narrative interviews with purposively selected participants.
RESULTS: 405 participants were recruited from February 2016 to April 2017. Median age was 35 years (IQR: 28-41), 67.9% (275/405) were male, and 60.6% (244/405) were HIV-positive. Employment and incomes were lowest at TB-treatment completion, with limited recovery in the following year: fewer people were in paid work (63.0% (232/368) vs 72.4% (293/405), p=0.006), median incomes were lower (US$44.13 (IQR: US$0-US$106.15) vs US$72.20 (IQR: US$26.71-US$173.29), p<0.001), and more patients were living in poverty (earning <US$1.90/day: 57.7% (211/366) vs 41.6% (166/399), p<0.001) 1 year after TB-treatment completion compared with before TB-disease onset. Half of the participants (50.5%, 184/368) reported ongoing dissaving (use of savings, selling assets, borrowing money) and 9.5% (35/368) reported school interruptions in the year after TB-treatment completion. Twenty-one participants completed in-depth interviews. Reported barriers to economic recovery included financial insecurity, challenges rebuilding business relationships, residual physical morbidity and stigma.
CONCLUSIONS: TB-affected households remain economically vulnerable even after TB-treatment completion, with limited recovery in income and employment, persistent financial strain requiring dissaving, and ongoing school interruptions. Measures of the economic impact of TB disease should include the post-TB period. Interventions to protect the long-term health and livelihoods of TB survivors must be explored. © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ.

Entities:  

Keywords:  Pulmonary tuberculosis; TB sequelae; health economics; post-TB lung disease; social determinants

Mesh:

Year:  2020        PMID: 33443228      PMCID: PMC7982936          DOI: 10.1136/thoraxjnl-2020-215338

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  6 in total

1.  Clinical standards for the assessment, management and rehabilitation of post-TB lung disease.

Authors:  G B Migliori; F M Marx; N Ambrosino; E Zampogna; H S Schaaf; M M van der Zalm; B Allwood; A L Byrne; K Mortimer; R S Wallis; G J Fox; C C Leung; J M Chakaya; B Seaworth; A Rachow; B J Marais; J Furin; O W Akkerman; F Al Yaquobi; A F S Amaral; S Borisov; J A Caminero; A C C Carvalho; D Chesov; L R Codecasa; R C Teixeira; M P Dalcolmo; S Datta; A-T Dinh-Xuan; R Duarte; C A Evans; J-M García-García; G Günther; G Hoddinott; S Huddart; O Ivanova; R Laniado-Laborín; S Manga; K Manika; A Mariandyshev; F C Q Mello; S G Mpagama; M Muñoz-Torrico; P Nahid; C W M Ong; D J Palmero; A Piubello; E Pontali; D R Silva; R Singla; A Spanevello; S Tiberi; Z F Udwadia; M Vitacca; R Centis; L D Ambrosio; G Sotgiu; C Lange; D Visca
Journal:  Int J Tuberc Lung Dis       Date:  2021-10-01       Impact factor: 3.427

Review 2.  Breathing Back Better! A State of the Art on the Benefits of Functional Evaluation and Rehabilitation of Post-Tuberculosis and Post-COVID Lungs.

Authors:  Emanuele Pontali; Denise Rossato Silva; Florian M Marx; Jose Antonio Caminero; Rosella Centis; Lia D'Ambrosio; Jose Maria Garcia-Garcia; Jeremiah Chakaya Muhwa; Simon Tiberi; Giovanni Battista Migliori
Journal:  Arch Bronconeumol       Date:  2022-06-10       Impact factor: 6.333

3.  "I'm suffering for food": Food insecurity and access to social protection for TB patients and their households in Cape Town, South Africa.

Authors:  Lieve Vanleeuw; Wanga Zembe-Mkabile; Salla Atkins
Journal:  PLoS One       Date:  2022-04-26       Impact factor: 3.752

4.  Protocol for a single-centre mixed-method pre-post single-arm feasibility trial of a culturally appropriate 6-week pulmonary rehabilitation programme among adults with functionally limiting chronic respiratory diseases in Malawi.

Authors:  Fanuel Meckson Bickton; Talumba Mankhokwe; Rebecca Nightingale; Cashon Fombe; Martha Mitengo; Langsfield Mwahimba; Wilfred Lipita; Laura Wilde; Ilaria Pina; Zainab K Yusuf; Zahira Ahmed; Martin Kamponda; Felix Limbani; Harriet Shannon; Enock Chisati; Andy Barton; Robert C Free; Michael Steiner; Jesse A Matheson; Adrian Manise; Sally J Singh; Jamie Rylance; Mark Orme
Journal:  BMJ Open       Date:  2022-01-31       Impact factor: 2.692

5.  Lifetime burden of disease due to incident tuberculosis: a global reappraisal including post-tuberculosis sequelae.

Authors:  Nicolas A Menzies; Matthew Quaife; Brian W Allwood; Anthony L Byrne; Anna K Coussens; Anthony D Harries; Florian M Marx; Jamilah Meghji; Debora Pedrazzoli; Joshua A Salomon; Sedona Sweeney; Sanne C van Kampen; Robert S Wallis; Rein M G J Houben; Ted Cohen
Journal:  Lancet Glob Health       Date:  2021-12       Impact factor: 26.763

6.  Costs of Tuberculosis at 3 Treatment Centers, Canada, 2010-2016.

Authors:  Jonathon R Campbell; Placide Nsengiyumva; Leslie Y Chiang; Frances Jamieson; Hadeel Khadawardi; Henry K-H Mah; Olivia Oxlade; Hayden Rasberry; Elizabeth Rea; Kamila Romanowski; Natasha F Sabur; Beate Sander; Aashna Uppal; James C Johnston; Kevin Schwartzman; Sarah K Brode
Journal:  Emerg Infect Dis       Date:  2022-09       Impact factor: 16.126

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.